# US 2022/0064292 A1 · Drug regulated transgene expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064292 A1
- Document ID: US20220064292A1
- Status: Published application
- Kind: A1
- Application number: 17/472,284
- Filed: 2021-09-10
- Published: 2022-03-03
- Earliest claimed: 2014-04-10
- Assignees: Seattle Children's Hospital (dba Seattle Children's Research Institute)
- Applicants: Seattle Children's Hospital (dba Seattle Children's Research Institute)
- Inventors: Michael C. Jensen
- Web page: https://patentgrep.com/patent/US20220064292A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 38/179: {for growth factors; for growth regulators}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 14/71: for growth factors; for growth regulators
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/32: against translation products of oncogenes
- C12N 5/0636: {T lymphocytes}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N 15/85: for animal cells
- C12Y 207/10001: Receptor protein-tyrosine kinase (2.7.10.1)
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/572: {cytotoxic response}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/53: Hinge
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 2510/00: Genetically modified cells
- C12N 2800/90: Vectors containing a transposable element
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor under the control of an inducible promoter. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain under the control of a drug inducible promoter. Controlling the expression of the chimeric receptor provides for the ability to turn expression on and off depending on the status of the patient. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.

## Claims

### Claim 1

(canceled)

### Claim 2

A method for inducing expression of a polypeptide in a subject, comprising:
(a) administering a cell to the subject, wherein the cell comprises:
a first nucleic acid comprising an inducible first promoter comprising a nucleotide sequence having at least 95% sequence identity with the nucleotide sequence set forth in SEQ ID NO:41, wherein the first nucleic acid is operably linked to a polynucleotide encoding the polypeptide, and
a second nucleic acid comprising a second promoter operably linked to a nucleic acid encoding a transcriptional activator for the first promoter; and
(b) administering to the subject an agent selected from the group consisting of tamoxifen, a metabolite of tamoxifen, and an analog of tamoxifen.

### Claim 3 (depends on 2)

The method of claim 2, wherein the agent is a metabolite of tamoxifen.

### Claim 4 (depends on 3)

The method of claim 3, wherein the agent is selected from 4-hydroxytamoxifen, a desmethyl-metabolite of tamoxifen, or a 4-hydroxy-metabolite of tamoxifen.

### Claim 5 (depends on 2)

The method of claim 2, wherein step (a) further comprises culturing the cell in the presence of tamoxifen, a metabolite of tamoxifen, or an analog of tamoxifen, prior to the administration.

### Claim 6 (depends on 5)

The method of claim 5, further comprising culturing the cell in the presence of an activating stimulator selected from anti-CD3 and anti-CD28.

### Claim 7 (depends on 2)

The method of claim 2, wherein the second promoter is a constitutive promoter.

### Claim 8 (depends on 7)

The method of claim 7, wherein the second promoter is an EF1a promoter.

### Claim 9 (depends on 2)

The method of claim 2, wherein the transcriptional activator comprises an HEA-3 polypeptide.

### Claim 10 (depends on 9)

The method of claim 9, wherein the transcriptional activator comprises a polypeptide having at least 95% sequence identity with the amino acid sequence set forth in SEQ ID NO:40.

### Claim 11 (depends on 2)

The method of claim 2, wherein the polypeptide is selected from a chimeric antigen receptor (CAR), a cytokine, a chemokine receptor

### Claim 12 (depends on 2)

The method of claim 2, wherein the cell is a T cell, a precursor T cell or a hematopoietic stem cell.

### Claim 13 (depends on 12)

The method of claim 12, wherein the cell is a CD4+ T cell, or a CD8+ T cell.

### Claim 14 (depends on 13)

The method of claim 13, wherein the cell is a CD8+ cytotoxic T cell selected from the group consisting of a naïve CD8+ T cell, a central memory CD8+ T cell, an effector memory CD8+ T cell, and a bulk CD8+ T cell.

### Claim 15 (depends on 13)

The method of claim 13, wherein the cell is a CD4+ T helper cell selected from the group consisting of a naïve CD4+ T cell, a central memory CD4+ T cell, an effector memory CD4+ T cell, and a bulk CD4+ T cell.

### Claim 16 (depends on 2)

The method of claim 2, wherein the cell is autologous to the subject.

### Claim 17 (depends on 2)

The method of claim 2, wherein the cell is allogeneic to the subject.

### Claim 18 (depends on 2)

The method of claim 2, wherein the subject is human.

### Claim 19

A method for inducing expression of a polypeptide in a cell, comprising contacting a cell with an agent selected from the group consisting of tamoxifen, a metabolite of tamoxifen, and an analog of tamoxifen, wherein the cell comprises:
a first nucleic acid comprising an inducible first promoter comprising a nucleotide sequence having at least 95% sequence identity with the nucleotide sequence set forth in SEQ ID NO:41, wherein the first nucleic acid is operably linked to a polynucleotide encoding the polypeptide, and
a second nucleic acid comprising a second promoter operably linked to a nucleic acid encoding a transcriptional activator for the first promoter.

### Claim 20 (depends on 19)

The method of claim 19, further comprising culturing the cell in the presence of the agent and an activating stimulator selected from anti-CD3 and anti-CD28.

### Claim 21 (depends on 19)

The method of claim 19, wherein the transcriptional activator comprises a polypeptide having at least 95% sequence identity with the amino acid sequence set forth in SEQ ID NO:40.
